Incannex Healthcare Inc. (IXHL): Depreciation & Amortization
$240.0K
Year ended 2026-06-30
$176.0K
Trailing 12 months to 2026-09-30
+39.7%
3-year compound annual growth
| Period ended | Depreciation & Amortization | Change YoY | Source filing |
|---|---|---|---|
| 2026-06-30 | $240.0K | -2.4% | 2026-09-25, From 2025-07-01 |
| 2025-06-30 | $246.0K | +138.8% | 2026-09-25, From 2024-07-01 |
| 2024-06-30 | $103.0K | +17.0% | 2025-09-29, From 2023-07-01 |
| 2023-06-30 | $88.0K | n/a | 2024-09-30, From 2022-07-01 |
Depreciation & Amortization at similar companies
| Company | Year ended | Depreciation & Amortization | Change YoY |
|---|---|---|---|
| Incannex Healthcare Inc. (IXHL) | 2026-06-30 | $240.0K | -2.4% |
| Bristol Myers Squibb Co (BMY) | 2025-12-31 | $4.01B | -58.2% |
| TherapeuticsMD, Inc. (TXMD) | 2025-12-31 | $384.0K | -24.6% |
| Eli Lilly & Co (LLY) | 2025-12-31 | $2.00B | +13.0% |
| Pfizer Inc (PFE) | 2025-12-31 | $6.59B | -6.0% |
| Johnson & Johnson (JNJ) | 2025-12-28 | $7.50B | +2.2% |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $13.84M | -2.6% |
| Lisata Therapeutics, Inc. (LSTA) | 2025-12-31 | $146.0K | -16.1% |
| Heron Therapeutics, Inc. (HRTX) | 2025-12-31 | $2.31M | -7.1% |
Compare IXHL, BMY, TXMD, LLY side by side · Screen every company in Pharmaceutical Preparations ↗